Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies

Figure 7

Cross-sectional analysis of counts of five subpopulations of CD8+ cytotoxic T-cell stratified by treatment (GAD65-alum (Diamyd)/placebo) presented using boxplots at study follow-up visits 0, 2, 4, 6, 8, and 10. Children treated with GAD65-alum had statistically significantly lower cell counts of (a) CD3 + CD8+ cytotoxic T-cells at visits 8 and 10, (b) CD8 + CD45RA + CD45RO-naïve cytotoxic T-cells at visits 8 and 10, (c) CD8 + CD45RA + CD62L+ naïve cytotoxic T-cells at visits 8 and 10, (d) CD8 + CD62L+ naïve cytotoxic T-cells at visit 10, and (e) CD8 + CD62L-effector memory cytotoxic T-cells at visit 8 compared to the placebo group. The estimates, 95% confidence intervals, and values for these results are provided in the figure, and complete results are presented in the Supplementary Table 2.

(a)

(b)

(c)

(d)

(e)